Merck & Co.
AWARDS
NEWS
The American Society of Clinical Oncology 2020 meeting was held virtually this year due to the COVID-19 pandemic. As usual, there were literally hundreds of abstracts, posters and presentations. Here’s a look at some of the highlights.
Numerous biopharmaceutical companies and researchers are presenting research and clinical trial results, and many have been announcing their plans for several weeks.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 26, 2020.
Merck has largely stayed out of the COVID-19 battle, but exploded into it with three major deals and collaborations today.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
Clovis Oncology’s Rubraca remained the only PARP inhibitor approved for prostate cancer for only a handful of days. Today, that medication is joined by AstraZeneca’s and Merck’s powerhouse PARP inhibitor, Lynparza.
JOBS
IN THE PRESS